Formulations for Trokendi XR transferred to Catalent for commercial manufacturing
Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has entered into an agreement with speciality pharmaceuticals company Supernus Pharmaceuticals whereby Catalent is the supplier of Trokendi XRM extended release capsules for Supernus.
Supernus developed Trokendi XR using its own advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.
Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the US market. Trokendi XR is a convenient alternative to current immediate release formulation products that require patients to administer their medication multiple times per day.
'We offer customers integrated solutions that include both proprietary drug delivery technologies and advanced supply solutions for oral controlled release development and commercial products,' said Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business. 'We are pleased to have been selected by Supernus to work on this unique epilepsy product.'